Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A Hoosier Oncology Group study

Costantine Albany, Mary J. Brames, Christopher Fausel, Cynthia S. Johnson, Joel Picus, Lawrence H. Einhorn

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A Hoosier Oncology Group study'. Together they form a unique fingerprint.

Medicine & Life Sciences